How Are States Working to Lower Drug Costs?

Archived webcast: Experts discuss the latest strategies to manage rising drug spending.


How Are States Working to Lower Drug Costs?

The United States spends twice as much per capita on prescription drugs as other developed countries, and most Americans are concerned about rising drug prices. U.S. net spending on pharmaceuticals now exceeds $450 billion annually. And these mounting costs, especially in Medicaid, have placed an increased burden on state budgets.

On Tuesday, July 10, The Pew Charitable Trusts hosted an event exploring the latest steps states are taking to address rising drug costs as well as possible strategies to tackle spending in the future.

During the event, get insights, statistics, and commentary—and join the conversation—by following #PewRxTalk on Twitter with @PewHealth.

Watch the archived webcast. With expert insights from:

State Senator Ronald Caldwell (R-AR)

State Senator Yvanna Cancela (D-NV)

Kelly Coates, associate vice president, clinical support services, University of Texas Medical Branch at Galveston 

Allan Coukell, senior director, health programs, The Pew Charitable Trusts

Sean Dickson, officer, drug spending research initiative, The Pew Charitable Trusts

Jane Horvath, senior policy fellow, National Academy for State Health Policy

Mark Miller, vice president, health care, Laura and John Arnold Foundation

Erin Mershon, senior Washington correspondent, STAT (moderator)

John O'Brien, advisor to the Secretary and Deputy Assistant Secretary for Health Policy, U.S. Department of Health & Human Services

Hemi Tewarson, director, Center for Best Practices’ Health Division, National Governors Association

Date: Tuesday, July 10, 2018
Time: 12:30 p.m. EDT
Location: The Pew Charitable Trusts,
901 E St. NW, Washington, DC 20004
Rising Drug Costs
Rising Drug Costs

How States Can Address Rising Drug Costs

Quick View

How States Can Address Rising Drug Costs

Rising prescription drug costs have placed an increased burden on state budgets, spurring many policymakers to pursue solutions to lower drug spending for patients, payers, and state programs.